




FIG. 1

Adverse Event	Single Ascending Dose									
	Cohort A,B,C 0.003-0.2 mg/kg (N=3) n (%)	Cohort D 0.6 mg/kg (N=8) n (%)	Cohort E 2 mg/kg (N=8) n (%)	Cohort F 6 mg/kg (N=8) n (%)	Cohort G 15 mg/kg (N=8) n (%)	Cohort H 30 mg/kg (N=8) n (%)	Cohort K 45 mg/kg (N=6) n (%)	Cohort I 60 mg/kg (N=7) n (%)		
Any TEAE	2 (66.7)	4 (50.0)	4 (50.0)	7 (87.5)	6 (75.0)	6 (75.0)	6 (100.0)	6 (85.7)		
Any treatment related TEAE	2 (66.7)	2 (25.0)	4 (50.0)	4 (50.0)	2 (25.0)	5 (62.5)	5 (83.3)	6 (85.7)		
Any SAE	0	0	0	1 (12.5)*	0	0	0	0		
Any treatment related SAE	0	0	0	0	0	0	0	0		
Any TEAE leading to early disc.	0	0	0	0	0	0	0	0		

FIG. 2




FIG. 3A




FIG. 3B




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11




FIG. 12




FIG. 13